From: Mode of progression after radioembolization in patients with colorectal cancer liver metastases
Total | No extrahepatic metastases at baseline | Â | 48(53%) |
 | Complete response Partial response Stable disease Progressive disease | 0 (0%) 5 (10%) 13 (27%) 30 (63%) | |
 | Extrahepatic metastases at baseline |  | 42 (47%) |
 | Complete response Partial response Stable disease Progressive disease | 0 (0%) 0 (0%) 3 (7%) 39 (93%)* | |
Yttrium-90 Resin | No extrahepatic metastases at baseline | Â | 28(61%) |
 | Complete response Partial response Stable disease Progressive disease | 0 (0%) 1 (4%) 7 (25%) 20 (71%) | |
 | Extrahepatic metastases at baseline |  | 18 (39%) |
 | Complete response Partial response Stable disease Progressive disease | 0 (0%) 0 (0%) 2 (11%) 16 (89%) | |
Yttrium-90 Glass | No extrahepatic metastases at baseline | Â | 9 (45%) |
 | Complete response Partial response Stable disease Progressive disease | 0 (0%) 2 (22%) 2 (22%) 5 (56%) | |
 | Extrahepatic metastases at baseline |  | 11 (55%) |
 | Complete response Partial response Stable disease Progressive disease | 0 (0%) 0 (0%) 0 (0%) 11 (100%) | |
Holmium-166 | No extrahepatic metastases at baseline | Â | 11 (46%) |
 | Complete response Partial response Stable disease Progressive disease | 0 (0%) 2 (18%) 4 (36%) 5 (46%) | |
 | Extrahepatic metastases at baseline |  | 13 (54%) |
 | Complete response Partial response Stable disease Progressive disease | 0 (0%) 0 (0%) 1 (8%) 12 (92%) * |